Short-course radiation plus immunotherapy and chemo for cervical cancer
Treatments studied
Part of Cancer, Women’s health & pregnancy clinical trials.
This trial tests a new combination of short-course radiation, an immunotherapy drug called adebrelimab, and standard chemotherapy before surgery for locally advanced cervical cancer. It aims to see if this approach can shrink tumors more effectively.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a woman between 18 and 80 years old.
- You have been diagnosed with cervical cancer (squamous cell, adenocarcinoma, or adenosquamous) that has not spread to lymph nodes or other parts of the body.
- Your cancer has not been treated before with surgery, radiation, or systemic therapy.
- You have at least one tumor that can be measured on scans.
- You are in good overall health (able to do daily activities without major problems).
- You have adequate organ function as determined by blood tests.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a drug called adebrelimab combined with standard chemotherapy and radiation for cervical cancer. It may be an option for people with stage IIB to IVA cervical cancer who have not had prior treatment.
This trial tests whether adding a new immunotherapy drug (adebrelimab) to standard chemoradiation helps treat locally advanced cervical cancer better than chemoradiation alone.
This study tests whether adding immunotherapy to chemotherapy, then giving chemotherapy together with radiation, works better for advanced cervical cancer. It aims to improve cancer control and help people live longer, without major safety issues.
This trial tests a combination of cadonilimab (an immune-boosting drug) plus chemotherapy for locally advanced cervical cancer that hasn't been treated before. The goal is to see if this combination helps shrink tumors and improve outcomes before surgery.
This trial tests a new immunotherapy drug, cadonilimab, combined with standard chemotherapy followed by chemoradiation for locally advanced cervical cancer. The goal is to see if this combination works better than current treatments.
This trial tests a combination of three types of cancer-fighting drugs—an immunotherapy (camrelizumab), a targeted therapy (famitinib), and chemotherapy—to treat cervical cancer that has returned or spread. The goal is to see if this combination works better than standard treatment.
Hear when a new Cervical Neoplasms trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.